Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure

Endocrine Journal

Volumn 54, Issue 5, 2007, Pages 805-811

  Ohmura, Chie ^a   Watada, Hirotaka ^a   Shimizu, Tomoaki ^a   Sakai, Ken ^a   Uchino, Hiroshi ^a   Fujitani, Yoshio ^a   Kanazawa, Akio ^a   Hirose, Takahisa ^a   Kawamori, Ryuzo ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Azelnidipine; Diabetes mellitus; Diphenyl 1 pyrenylphosphine (DPPP); Hypertension; Lipid hydroperoxides; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; AMLODIPINE; ASCORBIC ACID; AZELNIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIPHENYL 1 PYRENYLPHOSPHINE; LIPID HYDROPEROXIDE; PHOSPHINE DERIVATIVE; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; AZETIDINE 2 CARBOXYLIC ACID; DIHYDROPYRIDINE DERIVATIVE; DIPHENYL-1-PYRENYLPHOSPHINE; DRUG DERIVATIVE; LIPID PEROXIDE; ORGANOPHOSPHORUS COMPOUND; PYRENE DERIVATIVE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; AGED; CHEMISTRY; COMPARATIVE STUDY; ERYTHROCYTE; HYPERTENSION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; VALIDATION STUDY;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ASCORBIC ACID; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIHYDROPYRIDINES; ERYTHROCYTES; FEMALE; HUMANS; HYPERTENSION; LIPID PEROXIDES; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PYRENES; VITAMIN E;

EID: 40649083850     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K07-063     Document Type: Article

References (41)

1. Sowers JR (2004) Treatment of hypertension in patients with diabetes. Arch Intern Med 164: 1850-1857.
2. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S (2005) Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165: 1410-1419.
3. Janero DR, Burghardt B, Lopez R (1998) Protection of cardiac membrane phospholipid against oxidative injury by calcium antagonists. Biochem Pharmacol 37: 4197-4203.
4. Mak IT, Weglicki WB (1990) Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 66: 1449-1452.
5. Ondrias K, Misik V, Gergel D, Stasko A (1989) Lipid peroxidation of phosphatidylcholine liposomes depressed by the calcium channel blockers nifedipine and verapamil and by the antiarrhythmic-antihypoxic drug stobadine. Biochim Biophys Acta 1003: 238-245.
6. Mason RP, Leeds PR, Jacob RF, Hough CJ, Zhang KG, Mason PE, Chuang DM (1999) Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem 72: 1448-1456.
7. Lupo E, Locher R, Weisser B, Vetter W (1994) In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol. Biochem Biophys Res Commun 203: 1803-1808.
8. Mak IT, Kramer JH, Freedman AM, Tse SY, Weglicki WB (1990) Oxygen radical-mediated injury of myocytes-protection by propranolol. J Mol Cell Cardiol 22: 687-695.
9. Mak IT, Boehme P, Weglicki WB (1992) Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res 70: 1099-1103.
10. Tulenko TN, Laury-Kleintop L, Walter MF, Mason RP (1997) Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection? Int J Cardiol 62 Suppl 2: S55-66.
11. Henry PD (1991) Antiperoxidative actions of calcium antagonists and atherogenesis. J Cardiovasc Pharmacol 18 Suppl 1: S6-10.
12. Mason RP, Walter MF, Trumbore MW, Olmstead EG, Jr., Mason PE (1999) Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 31: 275-281.
13. Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T (1989) Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker. Jpn J Pharmacol 51: 57-64.
14. Shinomiya K, Mizushige K, Fukunaga M, Masugata H, Ohmori K, Kohno M, Senda S (2004) Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. J Int Med Res 32: 170-175.
15. Akasaka K, Suzuki T, Ohrui H, Megro H: Study on aromatic phosphines for novel fluorometry of hydroperoxides(2) (1987) The determination of lipid hydroperoxides with diphenyl-1-pyrenylphosphine. Aanlytical letters 20: 797-807.
16. Akasaka K, Ijichi S, Watanabe K, Ohrui H, Meguro H (1992) High-performance liquid chromatography and post-column derivatization with diphenyl-1-pyrenylphosphine for fluorimetric determination of triacylglycerol hydroperoxides. J Chromatogr 596: 197-202.
17. Akasaka K, Ohrui H, Meguro H, Tamura M (1993) Determination of triacylglycerol and cholesterol ester hydroperoxides in human plasma by high-performance liquid chromatography with fluorometric postcolumn detection. J Chromatogr 617: 205-211.
18. Akasaka K, Ohrui H, Meguro H (1993) Simultaneous determination of hydroperoxides of phosphatidylcholine, cholesterol esters and triacylglycerols by column-switching high-performance liquid chromatography with a post-column detection system. J Chromatogr 622: 153-159.
19. Akasaka K, Ohata A, Ohrui H, Meguro H (1995) Automatic determination of hydroperoxides of phosphatidylcholine and phosphatidylethanolamine in human plasma. J Chromatogr B Biomed Appl 665: 37-43.
20. Noguchi N, Numano R, Kaneda H, Niki E (1998) Oxidation of lipids in low density lipoprotein particles. Free Radic Res 29: 43-52.
21. Okimoto Y, Warabi E, Wada Y, Niki E, Kodama T, Noguchi N (2003) A novel method of following oxidation of low-density lipoprotein using a sensitive fluorescent probe, diphenyl-1-pyrenylphosphine. Free Radic Biol Med 35: 576-585.
22. Okimoto Y, Watanabe A, Niki E, Yamashita T, Noguchi N (2000) A novel fluorescent probe diphenyl-1-pyrenylphosphine to follow lipid peroxidation in cell membranes. FEBS Letters 474: 137-140.
23. Takahashi M, Shibata M, Niki E (2001) Estimation of lipid peroxidation of live cells using a fluorescent probe, diphenyl-1-pyrenylphosphine. Free Radic Biol Med 31: 164-174.
24. Matot I, Manevich Y, Al-Mehdi AB, Song C, Fisher AB (2003) Fluorescence imaging of lipid peroxidation in isolated rat lungs during nonhypoxic lung ischemia. Free Radic Biol Med 34: 785-790.
25. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
26. Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M (1994) Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta 1215: 121-125.
27. Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW (1991) Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl) hydroxylysine in human skin collagen. Biochemistry 30: 1205-1210.
28. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR (1996) The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271: 9982-9986.
29. Naito Y, Shimozawa M, Manabe H, Nakabe N, Katada K, Kokura S, Yoshida N, Ichikawa H, Kon T, Yoshikawa T (2006) Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur J Pharmacol 546: 11-18.
30. Yamamoto E, Lai ZF, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, Ito T, Ogawa H, Kim-Mitsuyama S (2006) Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. J Hypertens 24: 2057-2069.
31. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, Rakugi H, Ogihara T, Horiuchi M (2004) Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 43: 263-269.
32. Miyazawa T, Suzuki T, Fujimoto K, Yasuda K (1992) Chemiluminescent simultaneous determination of phosphatidylcholine hydroperoxide and phosphatidylethanolamine hydroperoxide in the liver and brain of the rat. J Lipid Res 33: 1051-1059.
33. Miyazawa T, Fujimoto K, Suzuki T, Yasuda K (1994) Determination of phospholipid hydroperoxides using luminol chemiluminescence-high-performance liquid chromatography. Methods Enzymol 233: 324-332.
34. Hui SP, Murai T, Yoshimura T, Chiba H, Nagasaka H, Kurosawa T (2005) Improved HPLC assay for lipid peroxides in human plasma using the internal standard of hydroperoxide. Lipids 40: 515-522.
35. Polidori MC, Frei B, Rordorf G, Ogilvy CS, Koroshetz WJ, Beal MF (1997) Increased levels of plasma cholesteryl ester hydroperoxides in patients with subarachnoid hemorrhage. Free Radic Biol Med 23: 762-767.
36. Abuja PM, Albertini R (2001) Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin Chim Acta 306: 1-17.
37. Ma J, Kishida S, Wang GQ, Meguro K, Imuta H, Oonuma H, Iida H, Jo T, Takano H, Morita T, Nagai R, Nakajima T (2006) Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells. J Cardiovasc Pharmacol 47: 314-321.
38. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004) (2006) Hypertens Res 29 Suppl: S1-105.
39. Dzau VJ (2001) Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37: 1047-1052.
40. Zhang C, Hein TW, Wang W, Kuo L (2003) Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 92: 322-329.
41. Igarashi M, Hirata, A, Kadomoto, Y, Tominaga M (2006) Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. Endocr J 53: 493-501.